Cost-effectiveness of stem cell therapy versus standard of care for acute and subacute ischemic stroke
Soichiro Takamiya, Yasuhiro Morii, Toshiya Osanai, Kazuki Ohashi, Katsuhiko Ogasawara, Kiyohiro Houkin, Miki Fujimura · 2026
Read Cost-effectiveness of stem cell therapy versus standard of care for acute and subacute ischemic stroke by Soichiro Takamiya, Yasuhiro Morii, Toshiya Osanai, Kazuki Ohashi, Katsuhiko Ogasawara, Kiyohiro Houkin, Miki Fujimura (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0349756.txt.
Description
Soichiro Takamiya and colleagues asked a pricing question: at what cost would stem cell therapy for stroke be good value in Japan? A recent combined analysis of trials found the therapy helps patients after acute or early stroke, but the treatment will not be cheap. The team built a ten-year simulation comparing stem cells plus standard care against standard care alone.
The model tracked costs and quality-adjusted life years, the standard measure blending length and quality of life. Working backward from Japan's official value threshold, they solved for the therapy price at which the extra benefit justifies the extra cost. Health systems need exactly this number before a promising therapy can be covered, priced, and offered fairly.
Catalog record
| CREATOR | Soichiro Takamiya, Yasuhiro Morii, Toshiya Osanai, Kazuki Ohashi, Katsuhiko Ogasawara, Kiyohiro Houkin, Miki Fujimura |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33390 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |